CBD for Anxiety: The Gap Between Claims and Evidence

CBD (cannabidiol) products are now one of the most visible wellness categories in U.S. retail, and anxiety relief is the headline claim on most labels. Industry analysts have estimated annual U.S. CBD sales at several billion dollars. Demand is driven by personal testimonials, a plausible neuroscience story, and very aggressive marketing. The actual clinical-trial evidence for CBD in anxiety is thinner, less consistent, and more complicated than the industry suggests.

What the Evidence Actually Shows

The strongest evidence for CBD in anxiety-related conditions comes from three places. First, pharmaceutical-grade CBD (Epidiolex) is FDA-approved for several rare childhood epilepsy syndromes, where it is genuinely effective. Second, a handful of small but well-designed trials of high-dose oral CBD have shown acute anxiety-reducing effects in social anxiety disorder; the most cited is Bergamaschi et al. (2011), in which a single oral dose of 600 mg CBD significantly reduced anxiety during a simulated public-speaking test in 24 treatment-naive patients with social anxiety. Third, animal models consistently show anti-anxiety effects through the endocannabinoid system. The problem is the gap between those findings and what shoppers actually buy.

Most retail CBD products supply 10–50 mg of CBD per dose. The positive human anxiety trials used 300–600 mg. Whether the lower doses scale down proportionally is not established. Reviews (e.g., Blessing et al. 2015) describe CBD's dose-response curve as roughly bell-shaped (often called an inverted-U), meaning too little and too much both look worse than an intermediate dose — and the intermediate dose in the published anxiety trials sits well above what is in a typical gummy.

The Bioavailability Problem

Oral CBD bioavailability — the share of the dose that actually reaches the bloodstream — is roughly 6–20% and varies a lot between people and with food (a fatty meal can multiply absorption several-fold). That means a 25 mg gummy may put only about 1.5–5 mg into systemic circulation — a small fraction of the doses used in clinical trials. Sublingual tinctures (held under the tongue) absorb a bit better; vaporised CBD reaches the bloodstream most efficiently but carries lung-related risks of its own. An "effective oral dose" for everyday anxiety, if there is one, has not yet been pinned down in adequately powered trials.

Regulatory and Quality Issues

CBD sits in a regulatory grey zone in most markets. Independent testing has repeatedly found mislabelled retail CBD: in Bonn-Miller et al. (2017) — a JAMA research letter analysing 84 products purchased online — only about 31% were accurately labelled, with most under-labelled or over-labelled, and roughly one in five contained detectable THC. In the U.S., there is no pre-market FDA approval for CBD-content claims on these products. For a consumer spending $60–$120 a month on CBD for anxiety, the evidence that the product contains what it says, at a dose with a real shot at working, is not strong.